LTRN | Nirvana Systems Inc.

Tag Archives for " LTRN "

LTRN: Reviving Failed Oncology Drugs with AI

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Initiating Coverage We are initiating coverage of Lantern Pharma Inc., (NASDAQ:LTRN) with a current valuation of $28 per share. Lantern is a new type of drug development company employing artificial intelligence and big data to identify critical biomarkers and relevant indications for previously investigated compounds. This approach can reduce cost, advance development timelines and improve the probability of success for candidates. We base our valuation primarily on our estimates for a successful commercialization of LP-300 in non- or never smoker adenocarcinoma non-small cell lung cancer (NSCLC).

Continue reading
>